Nano Dimension Ltd - ADR vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Nano Dimension Ltd - ADR trades at $1.56 (market cap $328.52M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.47 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 6.9× Nano Dimension Ltd - ADR's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| NNDM | SLS | |
|---|---|---|
Market Cap | $328.52M | $2.27B |
Volume | 1,160,945 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $2.14 | $15.46 |
52-Week Low | $1.21 | $1.39 |
Typical Hold Time | 43 Days | — |
Enterprise Value | -$76.33M | $2.14B |
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.55, down 1.27% with bearish technical signals. The company shows revenue growth from $102M in 2025 to $121M in 2026 but continues to post significant losses with a -135.18% net income margin. Recent strategic moves include cost-cutting initiatives and leadership changes aimed at reducing cash burn. The stock faces headwinds from negative cash flow trends and persistent unprofitability despite improving sales.
Outlook remains challenging with substantial execution risks. The company's cash position of $758M provides runway, but continued losses and negative operating cash flow pose sustainability concerns. Investment opportunity exists if cost reductions translate to profitability, but high risk profile requires careful monitoring of quarterly execution against guidance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →